Free shipping on all orders over $ 500


Cat. No. M15101
Cemiplimab Structure

Libtayo; REGN-2810; cemiplimab-rwlc

Size Price Availability
1mg USD 430  USD430 4-7 Days
5mg USD 1290  USD1290 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99%, Endotoxin < 2 EU/mg
  • COA
  • MSDS
Biological Activity

Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Source: HEK293

In vivo: Cemiplimab (REGN2810) binds to the humanized PD-1 receptor and inhibits tumor growth in MC38 mice in human PD-1 knockout mice. REGN2810 has a high affinity for cynomolgus monkey PD-1, and its pharmacokinetics and toxicology were studied in cynomolgus monkey. High dose REGN2810 was well tolerated without adverse immune-related effects. In vitro: In cell-based assays, REGN2810 reversed PD-1-dependent attenuation of T-cell receptor signaling and enhanced human primary T-cell responses.

Chemical Information
CAS Number 1801342-60-8
Storage 4°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Krishnansu S Tewari, et al. N Engl J Med. Survival with Cemiplimab in Recurrent Cervical Cancer

[2] Alexander J Stratigos, et al. Lancet Oncol. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

[3] Ahmet Sezer, et al. Lancet. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

[4] Arnold Lee, et al. Drugs. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma

[5] Michael R Migden, et al. N Engl J Med. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Related PD-1/PD-L1 Products
Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.


Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.


Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

Human PD-L1 inhibitor I

Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM.

Abmole Inhibitor Catalog

Keywords: Cemiplimab, Libtayo; REGN-2810; cemiplimab-rwlc supplier, PD-1/PD-L1, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.